RET Proto Oncogene Mutation Analysis
The RET (Rearranged during Transfection) gene or RET proto-oncogene consists of 21 exons and is located in the long arm of chromosome 10. It encodes a receptor-type tyrosine kinase with an extracellular domain, a transmembrane domain, and an intracellular tyrosine kinase domain. The RET gene has an important role in cell signaling in neural tissue at the early stages of embryonic development.
The most common genetic alterations in the RET gene are point mutations and fusions. RET point mutations have been reported in multiple endocrine neoplasia (MEN2A, MEN2B) and medullary thyroid carcinoma. In contrast, RET fusion proteins have been reported in papillary thyroid and non-small cell lung adenocarcinomas. Mutations in the RET proto-oncogene are also associated with Hirschsprung disease (HSCR) and congenital central hypoventilation syndrome (CCHS).
MEN2 is an autosomal dominant cancer syndrome that is divided into 3 subtypes: MEN2A, MEN2B, and familial medullary thyroid carcinoma (FMTC). The characteristic features of MEN2A include medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism. Patients with MEN2B have distinctive facial features with large lips and may develop early-onset MTC, pheochromocytoma, mucosal neuromas. The majority of MEN2-related RET mutations occur in exons 13, 14, 15, and 16 resulting in a gain of function in RET protein.
Hirschsprung’s disease (HSCR) is a congenital disorder of impaired intestinal motility due to impaired development of enteric nerves in the colon. There are two clinical forms of HSCR that effect variable lengths of the colon. Short-segment HSCR accounts for 80% of cases and effects the descending colon and rectum. Long-segment HSCR accounts for 20% of cases and is more clinically severe. The incidence of HSCR is approximately 1 in 5,000 live births.
It may occur due to chromosome abnormalities, single gene disorders (both syndromic and non-syndromic), a combination of mutations in multiple genes, and unknown causes. Pathogenic RET variants are considered the most common cause of HSCR and mutations of the RET proto-oncogene accounts 50% of familial and 15–20% of sporadic cases of HSCR. Loss of function mutations in RET are related to HSCR including full or partial RET gene deletions. Disease-associated mutations are most commonly found in exons 2, 3, 5, 6, 9, 10, 12, 13 & 17. Most mutations are missense or nonsense codon change and a few splice-site mutations including large and small deletions.
Congenital central hypoventilation syndrome (CCHS) is a congenital disorder of the autonomic nervous system in which affected individuals hypoventilate during sleep, and less commonly while awake. RET mutations may be associated with CCHS development in individuals with HSCR.
Genetic testing of RET mutations involves sequencing, of either specific exons or the entire coding region. However, sequencing multiple exons is necessary for adequate genetic diagnosis as individuals may carry multiple RET gene mutations, both in sporadic and familial cases.
- As an aid in diagnosis of multiple endocrine neoplasia type A or B
- Aid in the diagnosis of Hirschsprung disease
- As an aid diagnosis of central hypoventilation syndrome
- Screening for carriers in the family at risk of developing the RET associated disease
- To assess the risk of developing aggressive MTC and MTC-associated neoplastic lesions, such as pheochromocytoma and parathyroid adenoma
- Prenatal screening for carrier with increased risk of RET associated disease
Positive:
- Presence of mutation such as missense, nonsense, splice site codon change and deletion/duplication of RET gene in exon 10, 11, 13 and 14 is consistent with diagnosed of MEN2A and exon 15 and 16 as MEN2B.
- Mutation of RET gene in exon 2, 3, 5, 6, 9, 10, 12, 13 & 17 is diagnosed as HSCR.
- Overlap between the exons is diagnosed as MEN2A and Hirschsprung disease
Negative:
- No mutation of RET gene in selected sequence as well as in entire RET coding region
No reportable variants were identified (Negative for mutation of RET gene in selected or entire coding region of RET gene)
Whole Blood (EDTA/Lavender top tube).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Thyroid. 2009 Jun;19(6):565-612. [PMID: 19469690]
- Genet Med. 2006 Nov;8(11):704-10. [PMID: 17108762]
- J Genet Couns. 2018;27:1411-1416. [PMID: 29951718]
- Thyroid. 2015 Jun;25(6):567-610. [PMID: 25810047]
- Histol Histopathol. 2013 Sep;28(9):1117-36. [PMID: 23605783]
- Genet Med 2011;13(9):755-764. [PMID: 21552134]
- J Biol Chem. 2015; 290: 11749–11761. [PMID: 25795775]
- Cancer. 2014;120:1920-31. [PMID: 24699901]
- Am J Respir Crit Care Med. 2010;181:626-44. [PMID: 20208042]
- J Pediatr Surg. 2008 Feb;43(2):325-9. [PMID: 18280283]
- Arch Surg. 1997;132:1022-5. [PMID: 9301617]